Novel Approaches to the Treatment of Type 2 Diabetes
Authors:
- 6 January 2009
- journal article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 22 (3) , 320-332
Abstract
The emergence of the glucoregulatory hormone, glucagon-like peptide-1, has expanded our understanding of glucose homeostasis. The glucoregulatory actions of glucagon-like peptide-1 include enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and reduction of food intake. Two approaches have been developed to potentiate the effects of glucagon-like peptide-1 in those with type 2 diabetes. The glucagon-like peptide-1 analogs, such as exenatide, and dipeptidyl peptidase-IV inhibitors, such as sitagliptin, are currently available whereas others are in the final stages of development. These agents effectively reduce hemoglobin A1c while providing the other benefits associated with increased glucagon-like peptide-1. They also offer the potential to preserve the β-cell function. The effects on cardiovascular disease, if any, are unknown. Based on the current evidence, these agents represent viable second-and third-line options in the management of type 2 diabetes.Keywords
This publication has 41 references indexed in Scilit:
- Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes MellitusAnnals of Internal Medicine, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2006
- Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 DiabetesAnnals of Pharmacotherapy, 2006
- Incretin Mimetics and Dipeptidyl Peptidase‐IV Inhibitors: Potential New Therapies for Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetesRegulatory Peptides, 2004
- Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed DiabetesJAMA, 2004
- Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 DiabetesDiabetes Care, 2004
- Pharmacologic Therapy for Type 2 Diabetes MellitusAnnals of Internal Medicine, 1999
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999